Home/Filings/4/0001439222-21-000013
4//SEC Filing

Miles Darrin 4

Accession 0001439222-21-000013

CIK 0001439222other

Filed

Feb 16, 7:00 PM ET

Accepted

Feb 17, 4:14 PM ET

Size

11.9 KB

Accession

0001439222-21-000013

Insider Transaction Report

Form 4
Period: 2021-02-14
Miles Darrin
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common stock

    2021-02-14+8,66614,541 total
  • Exercise/Conversion

    Common stock

    2021-02-16+92215,463 total
  • Tax Payment

    Common stock

    2021-02-162,91612,547 total
  • Exercise/Conversion

    Restricted stock units

    2021-02-169220 total
    Common stock (922 underlying)
  • Exercise/Conversion

    Restricted stock units

    2021-02-148,66617,334 total
    Common stock (8,666 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  • [F2]The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.
  • [F3]The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units vest in three equal annual installments.

Issuer

AGIOS PHARMACEUTICALS, INC.

CIK 0001439222

Entity typeother

Related Parties

1
  • filerCIK 0001840076

Filing Metadata

Form type
4
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 4:14 PM ET
Size
11.9 KB